A Study of Anti-PD-1 Antibody, Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer
Overview
- Phase
- Early Phase 1
- Intervention
- Sintilimab
- Conditions
- Esophageal Squamous Cell Carcinoma
- Sponsor
- Zhejiang Cancer Hospital
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- unacceptable toxicity
- Last Updated
- 6 years ago
Overview
Brief Summary
The purpose of this study is to test the the efficacy and safety of sintilimab in combination with chemoradiation before surgery for esophageal cancer.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically or cytologically confirmed esophageal squamous carcinoma
- •18≤age≤75
- •ECOG PS is 0-1
- •TanyN+M0 or T3-4NanyM0 tumors
- •Patients must have surgically resectable disease treatable by esophagectomy, as assessed by a thoracic surgeon
- •No prior chemotherapy,radiotherapy and immunotherapy
- •Disease must be clinically limited to the esophagus
- •No esophageal perforation and no active esophageal bleeding
- •No interstitial pneumonia or history of interstitial pneumonia
- •FEV1\>1.2L
Exclusion Criteria
- •Previous treatment with chemotherapy, radiotherapy or immunotherapy
- •Cervical esophageal cancer
- •Esophageal perforation or active esophageal bleeding
- •Interstitial pneumonia or history of interstitial pneumonia
- •Patients with evidence of metastatic disease
- •Chronic Hepatitis B or C infection (e.g. Hepatitis B surface Ag positive or detectable viral load for Hepatitis B or C). Patients with prior evidence of Hepatitis B or C without active infection are eligible
- •Autoimmune diseases (such as systemic lupus erythematosus, rheumatoid rthritis, inflammatory bowel disease, autoimmune thyroid disease), but allow the following diseases to enter the next stage of screening: type I diabetes, skin diseases without systemic treatment (such as vitiligo, psoriasis)
- •14 days before the first dose, the patient had an active infection that required systemic treatment
- •Inability to understand or may not comply with test requirements
Arms & Interventions
arm
Biological: Sintilimab For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1 Drug: Paclitaxel 50 mg/m\^2 IV Q3W day 1, day 8 and day 15 Drug: carboplatin AUC: 2 IV Q3W day 1, day 8 and day 15 Radiotherapy: 1.8 Gy/fraction ×23 fractions Monday to Friday total dose of 41.4 Gy
Intervention: Sintilimab
arm
Biological: Sintilimab For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1 Drug: Paclitaxel 50 mg/m\^2 IV Q3W day 1, day 8 and day 15 Drug: carboplatin AUC: 2 IV Q3W day 1, day 8 and day 15 Radiotherapy: 1.8 Gy/fraction ×23 fractions Monday to Friday total dose of 41.4 Gy
Intervention: carboplatin/paclitaxel
arm
Biological: Sintilimab For weight \<60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1 Drug: Paclitaxel 50 mg/m\^2 IV Q3W day 1, day 8 and day 15 Drug: carboplatin AUC: 2 IV Q3W day 1, day 8 and day 15 Radiotherapy: 1.8 Gy/fraction ×23 fractions Monday to Friday total dose of 41.4 Gy
Intervention: Radiation
Outcomes
Primary Outcomes
unacceptable toxicity
Time Frame: 1 year
"Unacceptable toxicity" is defined as any of the following toxicities: \>1 episode of grade 3/4 neutropenia or thrombocytopenia \<75,000/μL (despite prior dose reduction) during chemoradiation any toxicity that results in \>2 week cumulative delay in chemoradiation any toxicity that is attributed to durvalumab which results in a delay of \>8 weeks in surgery, i.e. surgery \>16 weeks from the end of radiation, for a potentially operable patient any reason that is attributed to durvalumab which leads to death within 30 days of surgery
pathologic complete response rate, pCR
Time Frame: 1 year
major pahological response, MPR
Time Frame: 1 year